Sensei Biotherapeutics (NASDAQ:FTH) Given New $69.00 Price Target at Guggenheim

Posted by Francis Steltz on Nov 5th, 2026

Sensei Biotherapeutics (NASDAQ:FTH – Free Report) had its price target lowered by Guggenheim from $70.00 to $69.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also commented on FTH. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. William Blair began coverage on Sensei Biotherapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They issued a “buy” rating and a $56.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $56.17.

Check Out Our Latest Stock Analysis on FTH

Sensei Biotherapeutics Trading Up 1.7%

Shares of Sensei Biotherapeutics stock opened at $19.99 on Wednesday. The firm has a market capitalization of $516.54 million, a PE ratio of -0.14 and a beta of -0.15. The stock has a fifty day simple moving average of $27.95. Sensei Biotherapeutics has a 12 month low of $7.45 and a 12 month high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). As a group, research analysts anticipate that Sensei Biotherapeutics will post -13.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming purchased a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth about $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sensei Biotherapeutics by 48.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock valued at $150,000 after buying an additional 1,760 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at about $307,000. Renaissance Technologies LLC grew its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.